← All Tenaya Therapeutics, INC filings

Tenaya Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
TNYA
Tenaya Therapeutics, INC
10-K: Tenaya Therapeutics Reports 2024 Results, Highlights Clinical Progress
Tenaya Therapeutics' 10-K filing summarizes the company's focus on developing gene therapies for heart disease, clinical trial progress, and financial position for the year ended December 31, 2024.
NASDAQ
TNYA
Tenaya Therapeutics, INC
10-K: Tenaya Therapeutics Files 10-K, Provides Update on Heart Disease Therapies
Tenaya Therapeutics' 10-K filing details its progress in developing gene and small molecule therapies for heart disease, including updates on clinical trials and manufacturing capabilities.